Tesamorelin: Research Overview, Mechanisms, and Current Evidence
Tesamorelin is a stabilized synthetic analog of growth hormone-releasing hormone (GHRH 1-44). It is approved by the US FDA as the prescription drug Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy, where it is given as a daily subcutaneous injection. Because it is a prescription drug, the framing here is research-use only. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Tesamorelin is a prescription drug. Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
Tesamorelin stimulates the pituitary to release growth hormone, which in turn raises IGF-1 and promotes breakdown of visceral fat.
- Binds the GHRH receptor to stimulate pulsatile release of growth hormone from the pituitary.
- Reported to raise insulin-like growth factor 1 (IGF-1) levels following growth hormone release.
- Studied for selectively reducing visceral (deep abdominal) fat while preserving subcutaneous fat.
- Reported in trials to lower triglycerides and reduce liver fat without clinically meaningful changes in glucose.
Areas of Research Interest
Published studies have examined tesamorelin primarily in HIV-associated fat accumulation, where it progressed through registration trials.
HIV-associated lipodystrophy
Studied in Phase III trials for reducing excess visceral abdominal fat, leading to FDA approval as Egrifta.
Liver fat
Investigated for reducing hepatic fat, a focus of more recent meta-analytic work.
Metabolic and lipid markers
Examined for effects on triglycerides, cholesterol ratios, and IGF-1.
Body composition
Studied for increases in lean body mass alongside reductions in trunk and visceral fat.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in published clinical trials and approved labeling, with sources. It describes what was administered in those studies and is not a protocol, recommendation, or guidance for use in humans or animals. Because tesamorelin is a prescription drug, this information is provided for research context only.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| HIV-associated abdominal fat (pooled Phase III RCTs) | 2 mg subcutaneous, once daily, for 26 to 52 weeks | Falutz 2010·DOI |
| HIV-associated abdominal fat (long-term safety extension) | 2 mg subcutaneous daily; visceral fat reduction of about 18 percent sustained over 52 weeks | Falutz 2008·DOI |
| Human research (regulatory status) | FDA-approved as tesamorelin (Egrifta) for HIV-associated lipodystrophy; a prescription drug provided here for research use only | Badran 2026·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2008 to 2026)
Peer-reviewed literature indexed on PubMed documents the registration trials of tesamorelin and a recent meta-analysis of its effects.
Body composition and liver fat (meta-analysis)
A 2026 meta-analysis of five randomized trials reported that tesamorelin significantly reduced visceral adipose tissue, trunk fat, hepatic fat percentage, and waist circumference, and increased lean body mass, without serious side effects or disruption of glucose control. PubMed·DOI
Phase III pooled analysis
A 2010 pooled analysis of two Phase III trials in 806 patients reported that tesamorelin 2 mg daily reduced visceral fat by about 15 percent versus placebo over 26 weeks while preserving subcutaneous fat and improving triglycerides and body image. PubMed·DOI
Long-term safety (52 weeks)
A 2008 extension study reported that tesamorelin 2 mg daily was generally well tolerated over 52 weeks with sustained reductions in visceral fat and triglycerides, and noted that the fat reduction did not persist after treatment stopped. PubMed·DOI
Research Questions
What is tesamorelin?
Tesamorelin is a stabilized GHRH analog that stimulates growth hormone release. It is FDA-approved as Egrifta to reduce excess abdominal fat in people with HIV-associated lipodystrophy.
What is the current state of human evidence?
Phase III trials and a 2026 meta-analysis show that tesamorelin 2 mg daily reduces visceral and liver fat and improves lipids, though the effects reverse once treatment stops.
What does the available safety literature suggest?
Trials report tesamorelin to be generally well tolerated, with adverse events such as arthralgia, myalgia, and injection-site reactions and no clinically meaningful changes in glucose. As a prescription drug, it should be used only under medical supervision.
Referenced Citations
Literature indexed on PubMed.
- Badran, A.S., et al. (2026). Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes. Res. Clin. Pract., 20(1), 2-12. PubMed·DOI
- Falutz, J., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J. Clin. Endocrinol. Metab., 95(9), 4291-4304. PubMed·DOI
- Falutz, J., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719-1728. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.